MXPA02012626A - Bis-arilsufonas. - Google Patents
Bis-arilsufonas.Info
- Publication number
- MXPA02012626A MXPA02012626A MXPA02012626A MXPA02012626A MXPA02012626A MX PA02012626 A MXPA02012626 A MX PA02012626A MX PA02012626 A MXPA02012626 A MX PA02012626A MX PA02012626 A MXPA02012626 A MX PA02012626A MX PA02012626 A MXPA02012626 A MX PA02012626A
- Authority
- MX
- Mexico
- Prior art keywords
- arylsulfones
- bis
- disorders
- diseases
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion proporciona compuestos farmaceuticamente activos que son utiles para el tratamiento de enfermedades o trastornos del sistema nervioso central.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21289400P | 2000-06-20 | 2000-06-20 | |
US23702500P | 2000-09-29 | 2000-09-29 | |
US23971300P | 2000-10-12 | 2000-10-12 | |
US26826101P | 2001-02-13 | 2001-02-13 | |
PCT/US2001/010848 WO2001098279A2 (en) | 2000-06-20 | 2001-06-08 | Bis-arylsulfones |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02012626A true MXPA02012626A (es) | 2003-04-25 |
Family
ID=27498914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02012626A MXPA02012626A (es) | 2000-06-20 | 2001-06-08 | Bis-arilsufonas. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20030225065A1 (es) |
EP (1) | EP1294701A2 (es) |
JP (1) | JP2004501141A (es) |
KR (1) | KR20030011093A (es) |
CN (1) | CN1217938C (es) |
AR (2) | AR028705A1 (es) |
AU (2) | AU6803901A (es) |
BR (1) | BR0111892A (es) |
CA (1) | CA2410447A1 (es) |
MX (1) | MXPA02012626A (es) |
MY (1) | MY124786A (es) |
NZ (1) | NZ523314A (es) |
PE (1) | PE20020063A1 (es) |
WO (1) | WO2001098279A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020063A1 (es) * | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
ATE417838T1 (de) * | 2001-08-10 | 2009-01-15 | Hoffmann La Roche | Arylsulfonyl-derivate mit 5-ht 6-rezeptor- affinität |
AU2003238339A1 (en) * | 2002-02-01 | 2003-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
US7452888B2 (en) | 2002-03-27 | 2008-11-18 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
US20040029865A1 (en) * | 2002-05-23 | 2004-02-12 | Acker Brad A. | Bis-arylsulfones |
DE10224556A1 (de) * | 2002-05-31 | 2004-01-08 | Grünenthal GmbH | 1-Dimethylamino- 3-(3-methoxy-phenyl)2-methyl-pentan-3-ol entaltendes Arzneimittel in verschiedenen Formulierungen |
AU2003259246A1 (en) * | 2002-07-29 | 2004-02-16 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
KR101157272B1 (ko) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | 5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체 |
US20050201965A1 (en) * | 2004-03-11 | 2005-09-15 | The Procter & Gamble Company | Personal cleansing compositions |
CN101203500B (zh) * | 2005-01-25 | 2013-08-21 | 格利尼公司 | 取代的芳胺化合物和它们作为5-ht6调节剂的用途 |
AU2006209216A1 (en) | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
MX2008016141A (es) | 2006-06-16 | 2009-02-04 | Lundbeck & Co As H | 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo. |
JP2010509266A (ja) | 2006-11-09 | 2010-03-25 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6阻害剤としてのアリールスルホニルピロリジン |
JP2011502146A (ja) | 2007-10-29 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換ジアゼパンオレキシン受容体アンタゴニスト |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
RU2443697C1 (ru) * | 2010-12-21 | 2012-02-27 | Александр Васильевич Иващенко | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения |
WO2013049272A2 (en) | 2011-09-29 | 2013-04-04 | Theraceutix, Llc | Composition and method for treatment of symptoms associated with various skin conditions |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
JP2018520187A (ja) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | 神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体 |
CN110117264B (zh) * | 2018-02-06 | 2023-06-09 | 广东东阳光药业有限公司 | 苯基砜衍生物及其在药物上的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851423A (en) | 1986-12-10 | 1989-07-25 | Schering Corporation | Pharmaceutically active compounds |
GB8914660D0 (en) | 1989-06-26 | 1989-08-16 | Fujisawa Pharmaceutical Co | Aniline derivatives,processes for production thereof and pharmaceutical compositions comprising the same |
EP0554377A4 (en) | 1990-10-22 | 1993-10-20 | Research Corporation Technologies, Inc. | Aryl and heteroaryl compounds having anti-retrovirus activity |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
WO1993018035A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
KR950704245A (ko) | 1992-10-21 | 1995-11-17 | 우에하라 아끼라 | N-t-부틸아닐린유사체 및 그것을 함유한 지질 저하제 |
DE4238994A1 (de) | 1992-11-19 | 1994-05-26 | Basf Ag | Aniline als Markierungsmittel für Mineralöle |
JPH0733735A (ja) * | 1993-07-26 | 1995-02-03 | Green Cross Corp:The | 新規ジフェニルスルホン誘導体 |
WO1997007790A1 (en) * | 1995-08-28 | 1997-03-06 | Interlab Corporation | Pharmaceutical compositions for the treatment of infectious diseases |
HUT76266A (en) * | 1995-10-31 | 1997-07-28 | Egyt Gyogyszervegyeszeti Gyar | New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components |
KR0183826B1 (ko) | 1996-03-04 | 1999-05-01 | 김광호 | 연마공정 후처리용 세정 용액 및 그를 이용하는 세정 방법 |
ATE296811T1 (de) | 1997-07-11 | 2005-06-15 | Smithkline Beecham Plc | Sulfonamid-derivate als 5-ht6 receptor antagonisten und verfahren zu ihrer herstellung |
GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
PE20020063A1 (es) * | 2000-06-20 | 2002-01-30 | Upjohn Co | Bis-arilsulfonas como ligandos del receptor de 5-ht |
-
2001
- 2001-06-04 PE PE2001000513A patent/PE20020063A1/es not_active Application Discontinuation
- 2001-06-08 US US10/312,028 patent/US20030225065A1/en not_active Abandoned
- 2001-06-08 KR KR1020027017268A patent/KR20030011093A/ko not_active Application Discontinuation
- 2001-06-08 MX MXPA02012626A patent/MXPA02012626A/es not_active Application Discontinuation
- 2001-06-08 CA CA002410447A patent/CA2410447A1/en not_active Abandoned
- 2001-06-08 AU AU6803901A patent/AU6803901A/xx active Pending
- 2001-06-08 US US09/877,308 patent/US6579870B2/en not_active Expired - Fee Related
- 2001-06-08 BR BR0111892-7A patent/BR0111892A/pt not_active IP Right Cessation
- 2001-06-08 EP EP01945931A patent/EP1294701A2/en not_active Withdrawn
- 2001-06-08 WO PCT/US2001/010848 patent/WO2001098279A2/en not_active Application Discontinuation
- 2001-06-08 JP JP2002504235A patent/JP2004501141A/ja active Pending
- 2001-06-08 NZ NZ523314A patent/NZ523314A/xx unknown
- 2001-06-08 CN CN01810679XA patent/CN1217938C/zh not_active Expired - Fee Related
- 2001-06-08 AU AU2001268039A patent/AU2001268039B2/en not_active Ceased
- 2001-06-12 AR ARP010102779A patent/AR028705A1/es unknown
- 2001-06-19 MY MYPI20012883 patent/MY124786A/en unknown
-
2003
- 2003-01-23 AR ARP030100199A patent/AR038309A2/es active IP Right Grant
- 2003-04-15 US US10/414,062 patent/US20030207866A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1217938C (zh) | 2005-09-07 |
AU2001268039B2 (en) | 2005-06-09 |
KR20030011093A (ko) | 2003-02-06 |
CA2410447A1 (en) | 2001-12-27 |
WO2001098279A3 (en) | 2002-08-01 |
JP2004501141A (ja) | 2004-01-15 |
BR0111892A (pt) | 2003-07-01 |
US20020037892A1 (en) | 2002-03-28 |
US20030207866A1 (en) | 2003-11-06 |
EP1294701A2 (en) | 2003-03-26 |
CN1433407A (zh) | 2003-07-30 |
US20030225065A1 (en) | 2003-12-04 |
WO2001098279A2 (en) | 2001-12-27 |
AR028705A1 (es) | 2003-05-21 |
AR038309A2 (es) | 2005-01-12 |
US6579870B2 (en) | 2003-06-17 |
PE20020063A1 (es) | 2002-01-30 |
NZ523314A (en) | 2004-12-24 |
MY124786A (en) | 2006-07-31 |
AU6803901A (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY124786A (en) | Bis-arylsulfones | |
HK1129103A1 (en) | Prodrugs of gaba analogs, compositions and uses thereof gaba | |
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
IN2005KO00312A (es) | ||
EP1383490A4 (en) | COMBINATION OF EPOTHILON ANALOGUES AND CHEMOTHERAPEUTICS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
AU2002220715A1 (en) | Indolsulfonyl compounds useful in the treatment of cns disorders | |
IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
EE200300559A (et) | Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
GB9716879D0 (en) | Treatment of attention deficit disorders | |
EP1032556A4 (en) | PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION | |
NO20014241D0 (no) | C16-umettede FP-selektive prostaglandinanaloger | |
AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
AU2002227895A1 (en) | Sulphonamides for the treatment of central nervous system diseases | |
MXPA02001204A (es) | Compuestos calciliticos. | |
DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
IL158186A0 (en) | Pharmaceutically active compounds and methods of use | |
AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
TWI245756B (en) | Improved process for the preparation of 1,3-substituted indenes | |
WO2004016604A3 (en) | Azabicyclic compounds are central nervous system active agents | |
HRP20030696A2 (en) | GlyT-1 INHIBITORS | |
MY131858A (en) | Active ingredient combination for the pharmacological therapy of nicotine dependence | |
CY1106922T1 (el) | Ενωσεις ισοκινολινυλ αροϋλ πυρρολης για την αγωγη των διαταραχων κεντρικου νευρικου συστηματος | |
GB0010496D0 (en) | Treatment of conditions of the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |